Gore debuts enhanced stent-graft
This article was originally published in The Gray Sheet
Executive Summary
W.L. Gore launches Viabahn stent graft endoprosthesis with heparin bioactive surface Sept. 4, following PMA approval July 31. The device is used for vascular bypass in the superficial femoral artery. With about 80,000 such procedures a year, the market is worth roughly $150 million, Gore says. The device's anticoagulant heparin-bonded surface improves on the original model, approved in June 2005. Marketing will be targeted at interventional cardiologists, vascular surgeons and interventional radiologists...